Phase I and II Study of Auranofin in Chronic Lymphocytic Leukemia (CLL)

Inclusion Criteria:

histologically confirmed B-cell chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), prolymphocytic leukemia arising from CLL/SLL or Richter's transformation according to WHO criteria who require therapy based on the 2008 revised IWCLL criteria.
Relapsed or refractory disease after receiving at least 1 prior therapy for CLL
At least 18 years old; ECOG status of 1 or less; life expectancy 2 months or greater
Adequate organ and marrow function (total bilirubin less than 1.5x IULN; ALT less than 2x IULN; serum creatinine less than 1.5x ULN)

Exclusion Criteria:

have had chemotherapy, radiotherapy or immunotherapy within 4 weeks prior to entering study
have not recovered from AEs due to agents administered more than 4 weeks prior
receiving any other investigational agent
known second malignancy that limits survival to less than 2 years
known HIV positive
uncontrolled intercurrent illness
pregnant or breastfeeding